Liver failure
-
Sarepta Shares ELEVIDYS Safety Update, Implements Steps to Enhance Safety for Non-Ambulatory Duchenne Patients
Sarepta Therapeutics is taking action to address safety concerns with its gene therapy ELEVIDYS for Duchenne muscular dystrophy after a second fatal liver failure case. The company is implementing a new immunosuppression regimen, pausing shipments for non-ambulatory patients, and halting dosing in its ENVISION study. Sarepta will discuss these developments in an investor call on June 16, 2025.
